We are live on ! Find out more
AEON icon

AEON Biopharma
AEON

73 hedge funds and large institutions have $205M invested in AEON Biopharma in 2022 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 12 increasing their positions, 6 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 6

33% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 6

3% more funds holding

Funds holding: 71 → 73 (+2)

1% more capital invested

Capital invested by funds: $202M → $205M (+$2.65M)

0.05% more ownership

Funds ownership: 1.04% → 1.09% (+0.05%)

Holders
73
Holders Change
+2
Holders Change %
+2.82%
% of All Funds
1.23%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
12
Reduced
6
Closed
6
Calls
$6K
Puts
–
Net Calls
+$6K
Net Calls Change
+$6K

Top Buyers

Rank Fund Capital Flow
1
Bank of Montreal
Bank of Montreal
Ontario, Canada
+$5.51M
2
UOC
UBS O'Connor
Illinois
+$5.13M
3
Parallax Volatility Advisers
Parallax Volatility Advisers
California
+$2.91M
4
FTCM
First Trust Capital Management
Illinois
+$2.45M
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$2.29M

Top Sellers

Rank Fund Capital Flow
1
LA
Linden Advisors
New York
-$5.51M
2
Citadel Advisors
Citadel Advisors
Florida
-$4.89M
3
LOAMU
Lombard Odier Asset Management (USA)
New York
-$1.22M
4
JP Morgan Chase
JP Morgan Chase
New York
-$1.01M
5
AR
Advisory Research
Illinois
-$991K
Name Holding Trade Value Shares
Change 		Change in
Stake
CCM
51
Context Capital Management
California
$487K – – –
AR
52
Advisory Research
Illinois
$468K -$991K -1,404 -68%
Blackstone Inc
53
Blackstone Inc
New York
$393K – – –
RCM
54
Rivernorth Capital Management
Florida
$392K – – –
NAM
55
Nexpoint Asset Management
Texas
$390K – – –
BCM
56
Basso Capital Management
Connecticut
$375K – – –
LA
57
Linden Advisors
New York
$367K -$5.51M -7,815 -94%
ACA
58
Arena Capital Advisors
California
$300K -$300K -425 -50%
WRBC
59
W.R. Berkley Corp
Connecticut
$246K – – –
CCM
60
Cinctive Capital Management
New York
$245K – – –
Citigroup
61
Citigroup
New York
$245K – – –
OCAM
62
Owl Creek Asset Management
New York
$245K +$245K +347 New
DFCM
63
Dark Forest Capital Management
Puerto Rico
$244K – – –
RCM
64
Robinson Capital Management
Michigan
$241K +$29.6K +42 +14%
TI
65
Tidal Investments
Wisconsin
$241K +$29.6K +42 +14%
KKRC
66
Kohlberg Kravis Roberts & Co
New York
$218K – – –
AA
67
Ancora Advisors
Ohio
$164K – – –
PCM
68
Pinz Capital Management
New York
$139K +$139K +197 New
6CM
69
683 Capital Management
New York
$98K – – –
UBS Group
70
UBS Group
Switzerland
$11K – – –
Bank of Montreal
71
Bank of Montreal
Ontario, Canada
$5.51K +$5.51M +7,815 New
MF
72
Magnetar Financial
Illinois
$2.16K +$2.16M +3,064 New
SCM
73
Segantii Capital Management
Hong Kong
$490 – – –
SCC
74
Spring Creek Capital
Kansas
– -$2.44M -3,472 Closed
LOAMU
75
Lombard Odier Asset Management (USA)
New York
– -$1.22M -1,736 Closed
1 2
3
4

AEON Hedge Fund Activity: Q2 2022 in Review

73 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in AEON Biopharma (AEON) for Q2 2022, worth a combined $205M — up 1.3% from $202M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new AEON positions and 6 closed out — a net gain of 2 holders — while 12 added to existing stakes and 6 trimmed.

The largest buyer was Bank of Montreal, opening a new position worth an estimated $5.51M. The largest seller was Linden Advisors, cutting an estimated $5.51M.

  • 73 institutional investors held AEON Biopharma (AEON) as of Q2 2022, up from 71 in Q1 2022.
  • Funds reported $205M of AEON Biopharma stock for Q2 2022, up 1.3% quarter-over-quarter.
  • 8 funds opened new AEON Biopharma positions in Q2 2022 and 6 closed out, a net change of +2 holders.
  • The largest AEON Biopharma buyer in Q2 2022 was Bank of Montreal, an estimated $5.51M added.
  • The largest AEON Biopharma seller in Q2 2022 was Linden Advisors, an estimated $5.51M sold.

Based on aggregated 13F filings for Q2 2022.